FGF21 Analogs of Sustained Action Enabled by Orthogonal Biosynthesis Demonstrate Enhanced Antidiabetic Pharmacology in Rodents

Fibroblast growth factor 21 (FGF21) mitigates many of the pathogenic features of type 2 diabetes, despite a short circulating half-life. PEGylation is a proven approach to prolonging the duration of action while enhancing biophysical solubility and stability. However, in the absence of a specific pr...

詳細記述

保存先:
書誌詳細
主要な著者: Mu, James, Pinkstaff, Jason, Li, Zhihua, Skidmore, Lillian, Li, Nina, Myler, Heather, Dallas-Yang, Qing, Putnam, Anna-Maria, Yao, Jun, Bussell, Stuart, Wu, Margaret, Norman, Thea C., Rodriguez, Carlos G., Kimmel, Bruce, Metzger, Joseph M., Manibusan, Anthony, Lee, Darin, Zaller, Dennis M., Zhang, Bei B., DiMarchi, Richard D., Berger, Joel P., Axelrod, Douglas W.
フォーマット: Artigo
言語:Inglês
出版事項: American Diabetes Association 2012
主題:
Pharmacology and Therapeutics
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3266413/
https://ncbi.nlm.nih.gov/pubmed/22210323
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/db11-0838
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料